101 – 110 of 317
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
-
Mark
Progressive improvement in wound healing with increased therapy in haemophilia B mice
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article
-
Mark
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.
(
- Contribution to journal › Article
- 2012
-
Mark
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
(
- Contribution to journal › Article
-
Mark
Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders
(
- Contribution to journal › Article
-
Mark
Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
(
- Contribution to journal › Letter
-
Mark
Differences between developed and developing countries in paediatric care in haemophilia
(
- Contribution to journal › Article